Compare PRCH & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRCH | RZLT |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 420.8M |
| IPO Year | 2019 | 2011 |
| Metric | PRCH | RZLT |
|---|---|---|
| Price | $16.73 | $4.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $18.63 | $9.67 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | 26.32 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $482,414,000.00 | N/A |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | $17.05 | N/A |
| P/E Ratio | $1,794.00 | ★ N/A |
| Revenue Growth | ★ 10.18 | N/A |
| 52 Week Low | $6.36 | $1.07 |
| 52 Week High | $19.44 | $11.46 |
| Indicator | PRCH | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 41.81 |
| Support Level | $9.15 | $2.91 |
| Resistance Level | $17.03 | $4.71 |
| Average True Range (ATR) | 0.70 | 0.27 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 12.96 | 3.73 |
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.